TFFP News and Press, TFF Pharmaceuticals Inc - Ordinary Shares From 08/04/21

AUSTIN, Texas, Aug. 04, 2021 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced t...

Augmenta Bioworks and and TFF Pharmaceuticals (NASDAQ:TFFP) announce positive in vitro data indicating that their lead anti-COVID-19 monoclonal antibody (mAb) therapy, AUG-3387, binds to and neutralizes the SARS-CoV-2 Delta variant (B.1.617.2). TFFP shares up 4.7% premarket at ...

Data Shows AUG-3387 Neutralizes SARS-CoV-2 Delta Variant in Infective Assays Supports Earlier Data Showing AUG-3387 Binds Strongly to Delta Variant in Addition to Wild-Type Spike Protein and Other Variants of Concern Catalent Selected as Contract Drug Manufacturing Organiz...

AUSTIN, Texas, July 28, 2021 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced t...

The shares of TFFP have slumped, most likely as a result of disappointment over an absence of a deal with one of the top mRNA vaccine producers. However, besides a host of programs developed alone or with partners, the TFF platform remains very relevant for both vaccines as well as th...

TFF Pharmaceuticals (TFFP) has completed enrollment for the Phase 1 clinical trial for Tacrolimus Inhalation Powder (inhaled tacrolimus). In the Single Ascending Dose phase, single doses of inhaled tacrolimus of 0.5 mg, 1.0 mg, 2.5 mg to 5.0 mg were administered to healthy subjects. Peak and ...

Inhaled Tacrolimus Powder Achieves Systemic Therapeutic Drug Levels Anticipate Additional Safety Data in 3Q 2021 Initiation of Lung Transplant Study Expected in 2H 2021 AUSTIN, Texas, July 13, 2021 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clin...

The company offers its ImmTOR platform with its ability to decrease specific immune system responses which can improve the performance of multiple therapies. We like these kinds of 'multiple shots on goal' situations and insiders seem to like it too, given the amount of insider buying...

TFF Pharmaceuticals (TFFP) and Augmenta Bioworks announces that AUG-3387 has been selected as the first lead monoclonal antibody for clinical development against COVID-19 under their Joint Development and Collaboration Agreement.Targeting the SARS-Cov2 spike protein, AUG-3387 was isolate...

MENLO PARK, Calif. and AUSTIN, Texas, June 22, 2021 (GLOBE NEWSWIRE) -- Augmenta Bioworks, a biotechnology company enabling breakthroughs in medicine through immune profiling, and TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and ...